What is the definition of Familial Atypical Multiple Mole Melanoma Syndrome?

Familial atypical multiple mole melanoma syndrome (FAMMM syndrome) is an inherited condition characterized by the presence of multiple moles. Atypical moles, also called dysplastic nevi, are benign but are associated with an increased risk of melanoma. They can occur sporadically (with no other cases in a family), but are a symptom of FAMMM when multiple family members are affected. FAMMM syndrome may also increase the risk of pancreatic cancer in addition to melanoma. FAMMM syndrome is marked by:
  • one or more 1st or 2nd degree relatives (parent, sibling, child, grandparent, grandchild, aunt, or uncle) with malignant melanoma;
  • many moles, some of which are atypical (asymmetrical, raised, or different shades of color) and often of different sizes; and
  • moles that have specific features when examined under a microscope.
FAMMM syndrome may be caused by mutations in the CDKN2A gene (in about 40% of cases) or CDK4 gene (in very rare cases). However, in about 60% of cases, the cause is unknown. Inheritance is autosomal dominant. Treatment for FAMMM syndrome typically involves surgery. Family members of people with this condition should have surveillance at periodic intervals for melanoma.

What are the alternative names for Familial Atypical Multiple Mole Melanoma Syndrome?

  • B-K mole syndrome
  • FAMM-PC syndrome
  • FAMMM syndrome
  • Familial atypical multiple mole melanoma-pancreatic carcinoma
  • Familial Clark nevus syndrome
  • Familial atypical mole syndrome
  • Familial atypical multiple mole melanoma-pancreatic carcinoma syndrome
  • Familial dysplastic nevus syndrome
  • Melanoma-pancreatic cancer syndrome
  • Familial Atypical Mole Melanoma Syndrome
  • Condition: Cutaneous Melanoma Metastases and Rare Non-Melanoma Skin Cancer
  • Journal: Anticancer research
  • Treatment Used: Electrochemotherapy
  • Number of Patients: 68
  • Published —
This study tested the safety and efficacy of using electrochemotherapy to treat patients with cutaneous melanoma metastases and rare non-melanoma skin cancer.
  • Condition: Human Cutaneous Malignant Melanoma
  • Journal: Cellular and molecular biology (Noisy-le-Grand, France)
  • Treatment Used: Guizhi Fuling Pills
  • Number of Patients: 0
  • Published —
The study researched the use of Guizhi Fuling pills for treating human cutaneous malignant melanoma.